ArticleFrontiers in nephrology2026
Development and validation of a routine urinalysis-based risk stratification model for IgA nephropathy in a multicenter real-world hospital population.
Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgA nephropathy (IgAN) is the most common primary glomerular disease worldwide. Routine urinalysis is universally accessible but underutilized for IgAN risk stratification. This study aimed to develop and validate a urinalysis-based risk stratification model for IgAN in a multicenter real-world hospital population. Methods: This retrospective multicenter study was based on routine urinalysis records from 8 hospitals. A total of 354 patients had biopsy-confirmed primary IgAN, and 18,002 controls had no documented IgAN diagnosis after electronic medical record (EMR) review. The dataset was randomly divided into a training cohort (70%) and a hold-out validation cohort (30%). LASSO penalized logistic regression was used for variable selection. Model performance was evaluated by discrimination, calibration, and decision curve analysis (DCA). Bootstrap validation with 1000 resamplings was performed. An 8-variable simplified model was additionally developed. Results: LASSO regression selected 13 variables for the primary full model. The primary model achieved an AUC of 0.849 (95% CI: 0.824-0.873) in the training cohort and 0.861 (95% CI: 0.833-0.890) in the validation cohort. Calibration was good in the training cohort (Brier score = 0.017), while moderate calibration deviation was observed in the validation cohort (Brier score = 0.020). The model yielded a high negative predictive value (>0.99). The 8-variable simplified model retained favorable discrimination with a validation AUC of 0.840. Conclusions: This routine urinalysis-based model may serve as an accessible laboratory-based risk stratification tool for identifying patients with relatively low or elevated predicted probability of IgAN in real-world hospital settings. It should be interpreted as an adjunct to clinical evaluation rather than as a stand-alone diagnostic test or replacement for renal biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.